



Office of Regulatory Research
Compliance
Institutional Biosafety Committee

TO: Members of the Institutional Biosafety Committee

FROM: Office of Regulatory Research Compliance

DATE: April 10th, 2026

SUBJECT: MEETING MINUTES

WHEN: 03/16/2025

WHERE: Zoom

TIME: 2:00PM to 4:00PM

MEMBERS PRESENT: Qiyi Tang Ph.D., Julian Wilson, MA, Phillip Roane, Jr., Ph.D., Hemayet Ullah, Ph.D.

MEMBERS ABSENT: Karl Manley Thompson, Ph.D.

GUEST: None

QUORUM: Yes

CALLED TO ORDER: 2:17PM

ADJOURNED: 3:08PM

REVIEW OF MINUTES

Minutes from 02/9/2026 were reviewed and unanimously approved.

NEW BUSINESS (0)

a) None

NEW PROTOCOLS (2)

IBC Number: IBC-2025-0106

Study Title: *TARGETING COLORECTAL CANCER WITH SURFACE FUNCTIONALIZED NIOSOMES CO-ENCAPSULATING 5-FU AND SN 38*

Principal Investigator: Amusa Adebayo, Ph.D. - HU-PHARM – CC1801 – Pharmaceutical Sciences

Primary Reviewer: Hemayet Ullah, Ph.D.

Secondary Reviewer: Dr. Karl Thompson, Ph.D. (Biosafety Officer)

Outcome: Revision

Motion: Motion to Revise application specifically to detail the following points raised:

- 1) Biosafety Information is needed for the chemotherapy drug that is to be used and the safeguards that will be taken to protect study personnel.
- 2) Revise section 6.0 to clarify that HT-29 is non-toxic.

Vote: For: 4, Against: 0, Abstaining: 0.

IBC Number: IBC-2025-0090

Study Title: *The Impact of Cutibacterium acnes on Prostate Epithelial Cell Transformation: A Focus on Androgen-Mediated Modulation*

Principal Investigator: Dr. Karl Manley Thompson, Ph.D. – HUCM-CC1514-Micorbiology

Primary Reviewer: Qiyi Tang, Ph.D.

Secondary Reviewer: Hemayet Ullah, Ph.D.

Outcome: Approved

Motion: Motion to Approve

Vote: For: 4, Against: 0, Abstaining: 0.

REVISION (1):

IBC Number: IBC-2025-0107

Study Title: *Stability of Reconstituted Cefiderocol in Diluents for Large Volumes Parenteral Solutions*

Principal Investigator: Amusa Adebayo, Ph.D. - HU-PHARM – CC1801 – Pharmaceutical Sciences

Primary Reviewer: Phillip Roane Jr., Ph.D.

Secondary Reviewer: Dr. Karl Manley Thompson, Ph.D.

Outcome: Revision Approved

Motion: Motion to Approve Revision

Vote: For: 4, Against: 0, Abstaining: 0.

CONTINUATIONS/RENEWALS (1)

IBC Number: IBC-2025-0040

Study Title: *Targeting the unique minus strand mRNA to stop replication of coronavirus without affecting host human cells (Patent Pending)*

Principal Investigator: Hemayet Ullah, Ph.D. – HU-COAS-CC1004-Biology

Biosafety Officer: Dr. Karl Manley Thompson, Ph.D.

Outcome: Renewal Approved

APPROVED PROTOCOLS (1)

IBC Number: IBC-2025-0107

Study Title: RD007184, Rincewind: *“Blood-Based Biomarker Pre-Screening with Elecsys® Phospho-Tau (217P) Plasma Immunoassay for TRAVELLER Study (WP45722)*

Principal Investigator: Thomas Obisesan, MD, MPH

Biosafety Officer: Dr. Karl Manley Thompson, Ph.D.

Outcome: Approve Pending Admin Review – FCOI’s needed.

OTHER BUSINESS (0)

ADJOURNMENT: 3:08PM